Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Priority Briefs

Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer

Marie-Claire Wagle, Joseph Castillo, Shrividhya Srinivasan, Thomas Holcomb, Kobe C. Yuen, Edward E. Kadel, Sanjeev Mariathasan, Daniel L. Halligan, Adrian R. Carr, Max Bylesjo, Paul R. McAdam, Sarah Lynagh, Koen M. Marien, Mark Kockx, Yannick Waumans, Shih-Min A. Huang, Mark R. Lackner and Zineb Mounir
Marie-Claire Wagle
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie-Claire Wagle
  • For correspondence: zineb.mounir@mail.mcgill.ca mariewagle@gmail.com
Joseph Castillo
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shrividhya Srinivasan
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Holcomb
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kobe C. Yuen
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward E. Kadel
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Edward E. Kadel
Sanjeev Mariathasan
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel L. Halligan
2Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel L. Halligan
Adrian R. Carr
2Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Max Bylesjo
2Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul R. McAdam
2Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Lynagh
2Fios Genomics, Nine Edinburgh Bioquarter, Edinburgh, United Kingdom.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koen M. Marien
3HistoGeneX, Antwerp, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Koen M. Marien
Mark Kockx
3HistoGeneX, Antwerp, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yannick Waumans
3HistoGeneX, Antwerp, Belgium.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yannick Waumans
Shih-Min A. Huang
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark R. Lackner
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zineb Mounir
1Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zineb.mounir@mail.mcgill.ca mariewagle@gmail.com
DOI: 10.1158/2326-6066.CIR-19-0568 Published July 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.

Abstract

Prostate cancer is the second leading cause of cancer-related death in men. Despite having a relatively lower tumor mutational burden than most tumor types, multiple gene fusions such as TMPRSS2:ERG have been characterized and linked to more aggressive disease. Individual tumor samples have been found to contain multiple fusions, and it remains unknown whether these fusions increase tumor immunogenicity. Here, we investigated the role of fusion burden on the prevalence and expression of key molecular and immune effectors in prostate cancer tissue specimens that represented the different stages of disease progression and androgen sensitivity, including hormone-sensitive and castration-resistant prostate cancer. We found that tumor fusion burden was inversely correlated with tumor mutational burden and not associated with disease stage. High fusion burden correlated with high immune infiltration, PD-L1 expression on immune cells, and immune signatures, representing activation of T cells and M1 macrophages. High fusion burden inversely correlated with immune-suppressive signatures. Our findings suggest that high tumor fusion burden may be a more appropriate biomarker than tumor mutational burden in prostate cancer, as it more closely associates with immunogenicity, and suggests that tumors with high fusion burden could be potential candidates for immunotherapeutic agents.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Immunology Research Online (http://cancerimmunolres.aacrjournals.org/).

  • Cancer Immunol Res 2020;8:844–50

  • Received July 24, 2019.
  • Revision received November 1, 2019.
  • Accepted April 17, 2020.
  • Published first April 22, 2020.
  • ©2020 American Association for Cancer Research.
View Full Text

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
Cancer Immunology Research: 8 (7)
July 2020
Volume 8, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
Marie-Claire Wagle, Joseph Castillo, Shrividhya Srinivasan, Thomas Holcomb, Kobe C. Yuen, Edward E. Kadel, Sanjeev Mariathasan, Daniel L. Halligan, Adrian R. Carr, Max Bylesjo, Paul R. McAdam, Sarah Lynagh, Koen M. Marien, Mark Kockx, Yannick Waumans, Shih-Min A. Huang, Mark R. Lackner and Zineb Mounir
Cancer Immunol Res July 1 2020 (8) (7) 844-850; DOI: 10.1158/2326-6066.CIR-19-0568

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
Marie-Claire Wagle, Joseph Castillo, Shrividhya Srinivasan, Thomas Holcomb, Kobe C. Yuen, Edward E. Kadel, Sanjeev Mariathasan, Daniel L. Halligan, Adrian R. Carr, Max Bylesjo, Paul R. McAdam, Sarah Lynagh, Koen M. Marien, Mark Kockx, Yannick Waumans, Shih-Min A. Huang, Mark R. Lackner and Zineb Mounir
Cancer Immunol Res July 1 2020 (8) (7) 844-850; DOI: 10.1158/2326-6066.CIR-19-0568
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Demographic Factors and Toxicity in PD-1 Therapy in Melanoma
  • Early-Life Microbiota Restricts Colonic Tumorigenesis
Show more Priority Briefs
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement